SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-039692
Filing Date
2020-08-12
Accepted
2020-08-12 16:15:01
Documents
64
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ngm-10q_20200630.htm 10-Q 2495737
2 EX-10.1 ngm-ex101_91.htm EX-10.1 16556
3 EX-31.1 ngm-ex311_6.htm EX-31.1 15926
4 EX-31.2 ngm-ex312_37.htm EX-31.2 15930
5 EX-32.1 ngm-ex321_7.htm EX-32.1 8701
  Complete submission text file 0001564590-20-039692.txt   8335737

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ngm-20200630.xml EX-101.INS 1788867
7 XBRL TAXONOMY EXTENSION SCHEMA ngm-20200630.xsd EX-101.SCH 55442
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ngm-20200630_cal.xml EX-101.CAL 41789
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ngm-20200630_def.xml EX-101.DEF 196203
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20200630_lab.xml EX-101.LAB 439692
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20200630_pre.xml EX-101.PRE 338922
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38853 | Film No.: 201095626
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences